Start here if you're new
what it is
ORIC is trying to make cancer drugs work longer by attacking the ways tumors learn to resist treatment.
how it gets paid
Last year Oric Pharma made n/a in revenue.
what just happened
ORIC finished 2024 with quarterly EPS of -$0.51, while the full-year loss narrowed to -$1.83 from -$1.96 in 2023.
At a glance
B+ balance sheet — decent shape, but not bulletproof
95/100 earnings predictability — you can trust these numbers
-$1.83 fy2024 eps est
1.45 beta
~$1B market cap
xvary composite: 53/100 — below average
What they do
ORIC is trying to make cancer drugs work longer by attacking the ways tumors learn to resist treatment.
ORIC wins, if it wins at all, by focusing on one ugly problem: cancer resistance. The company is targeting resistance across 3 areas, and that focus gives you a clearer shot than the usual biotech science-fair sprawl. Small molecule antagonist → a drug designed to block a target inside the body → so what: if that biology works, a 122-person company can matter long before it looks big.
How they make money
n/a
annual revenue
The products that matter
prostate cancer drug candidate
Rinzimetostat
Phase 1b data reported
Phase 1b data is on the board. The number that matters next is 2026, when a Phase 3 start is supposed to turn this from early promise into a real registration path.
lead asset
lung cancer drug candidate
Enozertinib
Phase 1b data reported
This is the second major 2026 catalyst. Another Phase 3 start means the company is not relying on one shot on goal.
lead asset
pre-revenue drug development
Clinical Pipeline
$99.0M 9M net loss
With no commercial revenue and a $99.0M loss in nine months, the pipeline is the entire business. There is no separate cash-generating segment hiding in the background.
the whole story
Key numbers
$1.83
2024 EPS est.
Estimated full-year loss per share for 2024, improved from -$1.96 in 2023. Plain English: the cash burn looks a bit less bad, not good.
95
earnings predictability
This looks ridiculous next to a clinical-stage biotech, so read it carefully: the losses have been steady, not that profits are around the corner.
1.45
beta
Beta → how violently a stock moves versus the market → so what: ORIC tends to swing about 45% more than the index.
122
employees
A 122-person team running a $1 billion cancer bet tells you this story is about data quality, not corporate scale.
Financial health
B+
strength
- balance sheet grade B+ — solid but not elite
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
B+ — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for ORIC right now.
source: institutional data · return history unavailable
What just happened
beat estimates
ORIC finished 2024 with quarterly EPS of -$0.51, while the full-year loss narrowed to -$1.83 from -$1.96 in 2023.
The simple story is that losses improved vs. prior year, but the company is still a pre-revenue clinical-stage biotech. Quarterly EPS moved from -$0.52 in Q4 2023 to -$0.51 in Q4 2024, which is improvement measured with a ruler, not a parade.
-$0.51
q4 eps
-$1.83
fy2024 eps est
95
earnings predictability
the number that mattered
The key number is -$1.83 because it shows ORIC is losing less money than the -$1.96 posted in 2023, but it is still losing money.
source:, 2024 quarterly EPS history
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
ORIC’s risk profile is brutally simple: no product revenue, ongoing losses, and a valuation that assumes the 2026 clinical calendar stays alive.
med
Phase 3 starts slipping past 2026
The current story leans heavily on two Phase 3 trial starts in 2026. If either slips, you are not just losing a catalyst. You are stretching the entire path to value realization.
Impact: a delay would undermine the premium 3.1x book multiple because the stock is already getting credit for progress that has not happened yet.
med
Losses continue while revenue stays at zero
ORIC lost $99.0M in the first nine months of fiscal 2025 and still has no commercial revenue. That is normal for this stage of biotech, but it also means the business depends on external funding and investor patience.
Impact: if the timeline stretches, dilution risk and financing pressure become easier to imagine and harder to dismiss.
med
The market is already paying above biotech asset value norms
At 3.1x book versus a 2.6x biotech average, ORIC is not priced like a busted shell. Investors are paying up for possibility.
Impact: if trial data disappoints or simply fails to de-risk the story fast enough, there is room for that premium to compress.
A $99.0M nine-month loss plus no commercial revenue means one missed clinical step would pressure both sentiment and funding assumptions at the same time.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
2026 Phase 3 start timing
This is the milestone the entire page keeps circling. If the timeline holds, the thesis survives. If it slips, the stock has to reprice the wait.
valuation
3.1x price-to-book versus 2.6x for biotech
That gap is not outrageous, but it is real. You want to see de-risking events show up before the premium gets larger.
cash burn
net loss trend from the current $99.0M nine-month level
Losses are expected here. What matters is whether spending is buying visible progress or just extending the wait.
stock behavior
price stability of 5 / 100
This number is basically telling you to expect mood swings. Position size and patience matter more here than they would in a steadier business.
Analyst rankings
earnings predictability
95 / 100
In human-speak, the reported numbers themselves are not chaotic. The pipeline outcome still is.
risk rank
3
That reads as roughly middle-of-the-road on safety. Better than the weakest names, nowhere close to defensive.
beta
1.45
The stock has tended to move more than the market. Translation: you should expect wider swings than the index gives you.
source: institutional data
Institutional activity
institutional ownership data for ORIC is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$10
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive